Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)

(2013) M. Valgimigli et al.   EUROPEAN HEART JOURNAL

Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials

(2013) Giulio G Stefanini et al.   LANCET

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study

(2013) Roxana Mehran et al.   LANCET

Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting

(2012) Marco Valgimigli et al.   CIRCULATION

Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents

(2012) Lorenz Räber et al.   CIRCULATION

3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents

(2012) Michael Maeng et al.   JACC-Cardiovascular Interventions

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

(2012) Byeong-Keuk Kim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis

(2012) Tullio Palmerini et al.   LANCET

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial

(2012) Edoardo Camenzind et al.   LANCET

Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents

(2011) Hyeon-Cheol Gwon et al.   CIRCULATION

Everolimus-Eluting Versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

(2011) Kyung Woo Park et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Pathology of Neoatherosclerosis in Human Coronary Implants

(2011) Gaku Nakazawa et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions

(2010) Laura Mauri et al.   AMERICAN HEART JOURNAL

Optical Coherence Tomography Assessment of In Vivo Vascular Response After Implantation of Overlapping Bare-Metal and Drug-Eluting Stents

(2010) Giulio Guagliumi et al.   JACC-Cardiovascular Interventions

Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization

(2010) Duk-Woo Park et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

(2010) Elvin Kedhi et al.   LANCET

Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

(2010) Klaus Rasmussen et al.   LANCET

Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents

(2010) Seung-Jung Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease

(2010) Gregg W. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents

(2010) Patrick W. Serruys et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation

(2009) Edoardo Camenzind et al.   AMERICAN HEART JOURNAL

Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation

(2009) Takeshi Kimura et al.   CIRCULATION

A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents

(2009) R. A. Byrne et al.   EUROPEAN HEART JOURNAL

Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents

(2008) Michael Joner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

(2008) Stephan Windecker et al.   LANCET

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial

(2008) Stephen D Wiviott et al.   LANCET